Stocklytics Platform
Asset logo for symbol HUMA
Humacyte
HUMA40
$4.83arrow_drop_down0.10%-$0.00
Penny Stock
Asset logo for symbol HUMA
HUMA40

$4.83

arrow_drop_down0.10%

Performance History

Chart placeholder
Key Stats
Open$4.91
Prev. Close$4.84
EPS-1.27
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$608.45M
PE Ratio-
LOWHIGH
Day Range4.81
5.09
52 Week Range1.96
9.97
Ratios
Revenue-
EBITDA Margin %-
EPS-1.27

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

About Humacyte (HUMA)

The stock price history for Humacyte, Inc. (HUMA) has shown a steady growth over the years. Despite some fluctuations, the overall trend has been positive. Investors have witnessed an increase in the value of HUMA stock, making it an attractive investment option. The company has consistently delivered strong financial performance, which has been reflected in its stock price. This upward trend is expected to continue as the company continues to expand its presence in the market.
In terms of market cap, Humacyte, Inc. (HUMA) has shown impressive growth. With a market cap of X billion dollars, the company has placed itself as a major player in the industry. This strong market cap is a testament to the company's success and its potential for future growth. Investors can have confidence in the stability and long-term prospects of HUMA.
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Laura E. Niklason M.D., Ph.D.
Headquarters
Durham
Employees
164
Exchange
NASDAQ
add Humacyte to watchlist

Keep an eye on Humacyte

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Humacyte's (HUMA) price per share?

The current price per share for Humacyte (HUMA) is $4.83. The stock has seen a price change of -$0 recently, indicating a -0.1% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Humacyte (HUMA)?

For Humacyte (HUMA), the 52-week high is $9.97, which is 106.2% from the current price. The 52-week low is $1.96, the current price is 146.68% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Humacyte (HUMA) a growth stock?

Humacyte (HUMA) has shown an average price growth of -4.94% over the past three years. It has received a score of 51 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Humacyte as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Humacyte (HUMA) stock price performance year to date (YTD)?

As of the latest data, Humacyte (HUMA) has a year-to-date price change of 67.3%. Over the past month, the stock has experienced a price change of -15.18%. Over the last three months, the change has been -21.25%. Over the past six months, the figure is -25.27%.
help

Is Humacyte (HUMA) a profitable company?

Humacyte (HUMA) has a net income of -$110.78M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$100.05M. Furthermore, the EBITDA is -$105.28M.
help

What is the market capitalization of Humacyte (HUMA)?

Humacyte (HUMA) has a market capitalization of $605.95M. The average daily trading volume is 4.88, indicating the stock's liquidity and investor engagement.

News

Humacyte’s (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman
HUMACYTE
FDA VIOLATIONS
REGULATORY SCRUTINY
STOCK PRICE DECLINE
Nov 15, 2024

Humacyte’s (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman

Humacyte (HUMA) Faces Questions After FDA Inspection – Hagens Berman
HUMACYTE
FDA
MANUFACTURING
DISCLOSURE
Nov 11, 2024

Humacyte (HUMA) Faces Questions After FDA Inspection – Hagens Berman

Humacyte (HUMA) Faces Questions After FDA Inspection – Hagens Berman
HUMACYTE
FDA
MANUFACTURING
DISCLOSURE
Oct 24, 2024

Humacyte (HUMA) Faces Questions After FDA Inspection – Hagens Berman

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors
HUMACYTE
FDA
SECURITIES LAWS
Oct 23, 2024

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors
HUMACYTE
FDA
SECURITIES LAWS
Oct 22, 2024

The Law Offices of Frank R. Cruz Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors

Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on September 30, 2024
HUMACYTE
ATEV
VASCULAR TRAUMA
BIOTECHNOLOGY
Sep 26, 2024

Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on September 30, 2024

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level